Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this retrospective study is to assess the outcome of patients with inflammatory bowel disease (IBD) under TNF-alpha antibody therapy over a period of 20 years
Long-term results published so far show that over the years a large part of patients have to stop TNF Alpha antibody therapy in IBD. Reasons are mostly loss of effectiveness or intolerance or side effects. Reasons for the termination are usually poorly characterized with regard to the exact reason and time. As a consequence, the aim of this retrospective study is to assess the outcome of patients with inflammatory bowel disease under TNF-alpha antibody therapy over a period of 20 years
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Ulcerative Colitis (UC) | This Group includes all patients suffering from UC who have been treated with a TNF Alpha antibody within the last 20 years at the IBD outpatient clinic at our Hospital. |
| |
| Crohn's disease (CD) | This Group includes all patients suffering from CD who have been treated with a TNF Alpha antibody within the last 20 years at the IBD outpatient clinic at our Hospital. |
| |
| IBD unclassified | This Group includes all patients suffering from IBD unclassified who have been treated with a TNF Alpha antibody within the last 20 years at the IBD outpatient clinic at our Hospital. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| TNF Alpha therapy | Other | Retrospective analysis of outcome of first TNF Alpha therapy |
|
| Measure | Description | Time Frame |
|---|---|---|
| Length of first TNF Alpha Therapy in IBD patients | The main endpoint of this retrospective Analysis is the length of Treatment with the first TNF Alpha therapy in IBD | 20 years |
| Measure | Description | Time Frame |
|---|---|---|
| Rate of further biologicals after first TNF Alpha therapy | Follow-up drug therapy after termination of TNF Alpha therapy | 20 years |
| Rate of surgical interventions after first TNF Alpha | Resections after the termination of first TNF Alpha therapy |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
The study Population includes all patients with a confirmed IBD diagnosis who have been treated with an TNF Alpha antibody in the last 20 years at our outpatient clinic in Graz, Austria
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Wolfgang Petritsch, Prof | Meduni Graz | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Medical University of Graz | Graz | Austria |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 20 years |
| Reasons for discontinuing therapy | Loss of response, side effects etc. | 20 years |
| Predictive factors | Predictive factors for long-term response (BMI, CRP, Alb etc.) | 20 years |
| Number of side effects | Side effects of the primarily used TNF-alpha antibodies leading to discontinuation of the drug | 20 years |